Engineering building blocks for self-assembling protein nanoparticles

Microbial Cell Factories

Volumn 9, Issue , 2010, Pages

  Vázquez, Esther ^a,b   Villaverde, Antonio ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; NANOMATERIAL; NANOPARTICLE; OLIGOMER; PROTEIN SUBUNIT; RECOMBINANT DNA; DRUG; PROTEIN;

AMINO ACID SEQUENCE; DRUG DELIVERY SYSTEM; FLAGELLUM; NONHUMAN; NOTE; PROTEIN ASSEMBLY; PROTEIN ENGINEERING; CHEMISTRY; EDITORIAL; HUMAN; METHODOLOGY; NANOTECHNOLOGY;

DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; PROTEIN ENGINEERING; PROTEINS;

EID: 78650594882     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/1475-2859-9-101     Document Type: Note

References (64)

1. Douglas KL. Toward Development of Artificial Viruses for Gene Therapy: A Comparative Evaluation of Viral and Non-viral Transfection. Biotechnol Prog 2008, 24:871-883.
2. Mastrobattista E, van der Aa MA, Hennink WE, Crommelin DJ. Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 2006, 5:115-121. 10.1038/nrd1960, 16521330.
3. Wagner E. Strategies to improve DNA polyplexes for in vivo gene transfer: will "artificial viruses" be the answer?. Pharm Res 2004, 21:8-14. 10.1023/B:PHAM.0000012146.04068.56, 14984252.
4. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target 2008, 16:108-123. 10.1080/10611860701794353, 18274932.
5. Kaasgaard T, Andresen TL. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv 2010, 7:225-243. 10.1517/17425240903427940, 20095944.
6. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599. 10.1016/j.tips.2009.08.004, 19837467.
7. Singh S. Nanomedicine-nanoscale drugs and delivery systems. J Nanosci Nanotechnol 2010, 10:7906-7918. 10.1166/jnn.2010.3617, 21121278.
8. Betancourt T, Brannon-Peppas L. Micro- and nanofabrication methods in nanotechnological medical and pharmaceutical devices. Int J Nanomedicine 2006, 1:483-495. 10.2147/nano.2006.1.4.483, 2676643, 17722281.
9. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010, 7:479-495. 10.1517/17425240903579971, 20331355.
10. Tjalsma H. Identification of biomarkers for colorectal cancer through proteomics-based approaches. Expert Rev Proteomics 2010, 7:879-895. 10.1586/epr.10.81, 21142889.
11. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009, 1:12-25. 10.4161/mabs.1.1.7347, 2715180, 20046569.
12. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188:759-768. 10.1083/jcb.200910104, 2845077, 20231381.
13. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010, 28:2777-2783. 10.1200/JCO.2009.27.0777, 20406928.
14. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther 2010, 128:324-335. 10.1016/j.pharmthera.2010.07.007, 20705093.
15. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004, 27:85-131. 10.1016/j.mcn.2004.03.005, 15485768.
16. Aris A, Villaverde A. Modular protein engineering for non-viral gene therapy. Trends Biotechnol 2004, 22:371-377. 10.1016/j.tibtech.2004.05.004, 15245910.
17. Ferrer-Miralles N, Vazquez E, Villaverde A. Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol 2008, 26:267-275. 10.1016/j.tibtech.2008.02.003, 18358551.
18. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008, 1786:126-138.
19. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J 2007, 9:E18-E29. 10.1208/aapsj0901003, 2751301, 17408236.
20. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 2007, 4:631-651. 10.1021/mp700073y, 17880166.
21. Beck A, Klinguer-Hamour C, Bussat MC, Champion T, Haeuw JF, Goetsch L, et al. Peptides as tools and drugs for immunotherapies. Journal of Peptide Science 2007, 13:588-602. 10.1002/psc.852, 17602441.
22. Enback J, Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans 2007, 35:780-783. 10.1042/BST0350780, 17635147.
23. Balestrieri ML, Napoli C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer 2007, 43:1242-1250. 10.1016/j.ejca.2007.02.006, 17449238.
24. Fabre JW, Collins L. Synthetic peptides as non-viral DNA vectors. Curr Gene Ther 2006, 6:459-480. 10.2174/156652306777934865, 16918335.
25. Vazquez E, Ferrer-Miralles N, Mangues R, Corchero JL, Schwartz S, Villaverde A. Modular protein engineering in emerging cancer therapies. Curr Pharm Des 2009, 15:893-916. 10.2174/138161209787582084, 19275653.
26. Brown KC. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des 2010, 16:1040-1054. 10.2174/138161210790963788, 20030617.
27. Sidhu SS. Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 2000, 11:610-616. 10.1016/S0958-1669(00)00152-X, 11102798.
28. Deutscher SL. Phage display in molecular imaging and diagnosis of cancer. Chem Rev 2010, 110:3196-3211. 10.1021/cr900317f, 20170129.
29. Tanaka T, Kokuryu Y, Matsunaga T. Novel method for selection of antimicrobial peptides from a phage display library by use of bacterial magnetic particles. Appl Environ Microbiol 2008, 74:7600-7606. 10.1128/AEM.00162-08, 2607169, 18952877.
30. Uchida M, Klem MT, Allen M, Suci P, Flenniken M, Varpness Z, et al. Biological containers: Protein cages as multifunctional nanoplatforms. Adv Mater 2007, 19:1025-1042.
31. Maham A, Tang Z, Wu H, Wang J, Lin Y. Protein-Based Nanomedicine Platforms for Drug Delivery. Small 2009, 5:1706-1721. 10.1002/smll.200801602, 19572330.
32. Vazquez E, Ferrer-Miralles N, Villaverde A. Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today 2008, 13:1067-1074. 10.1016/j.drudis.2008.08.008, 18801457.
33. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 2009, 8:17. 10.1186/1475-2859-8-17, 2669800, 19317892.
34. Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodriguez-Carmona E, Baumann K, et al. Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact 2008, 7:11. 10.1186/1475-2859-7-11, 2322954, 18394160.
35. Rodriguez-Carmona E, Villaverde A. Nanostructured bacterial materials for innovative medicines. Trends Microbiol 2010, 18:423-430. 10.1016/j.tim.2010.06.007, 20674365.
36. Villaverde A. Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact 2010, 9:53. 10.1186/1475-2859-9-53, 2916890, 20602780.
37. Bar H, Yacoby I, Benhar I. Killing cancer cells by targeted drug-carrying phage nanomedicines. BMC Biotechnol 2008, 8:37. 10.1186/1472-6750-8-37, 2323368, 18387177.
38. Larocca D, Burg MA, Jensen-Pergakes K, Ravey EP, Gonzalez AM, Baird A. Evolving phage vectors for cell targeted gene delivery. Curr Pharm Biotechnol 2002, 3:45-57. 10.2174/1389201023378490, 11883506.
39. Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, et al. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide. Mol Cancer Res 2010, 8:135-144. 10.1158/1541-7786.MCR-09-0339, 20145035.
40. Zhao Y, Tanaka M, Kinoshita T, Higuchi M, Tan T. Self-assembling peptide nanofiber scaffolds for controlled release governed by gelator design and guest size. J Control Release 2010, 147:392-399. 10.1016/j.jconrel.2010.08.002, 20709121.
41. Zhao Y, Tanaka M, Kinoshita T, Higuchi M, Tan T. Nanofibrous scaffold from self-assembly of beta-sheet peptides containing phenylalanine for controlled release. J Control Release 2010, 142:354-360. 10.1016/j.jconrel.2009.11.016, 19932721.
42. Gelain F, Unsworth LD, Zhang S. Slow and sustained release of active cytokines from self-assembling peptide scaffolds. J Control Release 2010, 145:231-239. 10.1016/j.jconrel.2010.04.026, 20447427.
43. Kyle S, Aggeli A, Ingham E, McPherson MJ. Production of self-assembling biomaterials for tissue engineering. Trends Biotechnol 2009, 27:423-433. 10.1016/j.tibtech.2009.04.002, 2828541, 19497631.
44. Kyle S, Aggeli A, Ingham E, McPherson MJ. Recombinant self-assembling peptides as biomaterials for tissue engineering. Biomaterials 2010, 31:9395-9405. 10.1016/j.biomaterials.2010.08.051, 20932572.
45. Yan F, Zhang Y, Kim KS, Yuan HK, Vo-Dinh T. Cellular uptake and photodynamic activity of protein nanocages containing methylene blue photosensitizing drug. Photochem Photobiol 2010, 86:662-666. 10.1111/j.1751-1097.2009.00696.x, 20132513.
46. Bessa PC, Machado R, Nurnberger S, Dopler D, Banerjee A, Cunha AM, et al. Thermoresponsive self-assembled elastin-based nanoparticles for delivery of BMPs. J Control Release 2010, 142:312-318. 10.1016/j.jconrel.2009.11.003, 19913578.
47. Huang H, Sun XS. Rational design of responsive self-assembling peptides from native protein sequences (dagger). Biomacromolecules 2010, 11:3390-3394. 10.1021/bm100894j, 21080625.
48. Ventura S, Villaverde A. Protein quality in bacterial inclusion bodies. Trends Biotechnol 2006, 24:179-185. 10.1016/j.tibtech.2006.02.007, 16503059.
49. Martinez-Alonso M, Gonzalez-Montalban N, Garcia-Fruitos E, Villaverde A. Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact 2009, 8:4. 10.1186/1475-2859-8-4, 2630952, 19133126.
50. Garcia-Fruitos E, Villaverde A. Friendly production of bacterial inclusion bodies. Korean J Chem Eng 2010, 27:385-389.
51. Carrio M, Gonzalez-Montalban N, Vera A, Villaverde A, Ventura S. Amyloid-like properties of bacterial inclusion bodies. J Mol Biol 2005, 347:1025-1037. 10.1016/j.jmb.2005.02.030, 15784261.
52. Schrodel A, de Marco A. Characterization of the aggregates formed during recombinant protein expression in bacteria. BMC Biochem 2005, 6:10. 10.1186/1471-2091-6-10, 1175841, 15927061.
53. Martinez-Alonso M, Gonzalez-Montalban N, Garcia-Fruitos E, Villaverde A. The functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol 2008, 101:1353-1358.
54. Hartmann BM, Kaar W, Falconer RJ, Zeng B, Middelberg AP. Expression and purification of a nanostructure-forming peptide. J Biotechnol 2008, 135:85-91. 10.1016/j.jbiotec.2008.03.003, 18436322.
55. Hartmann BM, Kaar W, Yoo IK, Lua LH, Falconer RJ, Middelberg AP. The chromatography-free release, isolation and purification of recombinant peptide for fibril self-assembly. Biotechnol Bioeng 2009, 104:973-985. 10.1002/bit.22447, 19530081.
56. Riley JM, Aggeli A, Koopmans RJ, McPherson MJ. Bioproduction and characterization of a pH responsive self-assembling peptide. Biotechnol Bioeng 2009, 103:241-251. 10.1002/bit.22274, 19266471.
57. Saccardo P, Villaverde A, Gonzalez-Montalban N. Peptide-mediated DNA condensation for non-viral gene therapy. Biotechnol Adv 2009, 27:432-438. 10.1016/j.biotechadv.2009.03.004, 19341789.
58. Aris A, Villaverde A. Molecular organization of protein-DNA complexes for cell-targeted DNA delivery. Biochem Biophys Res Commun 2000, 278:455-461. 10.1006/bbrc.2000.3824, 11097858.
59. Aris A, Villaverde A. Engineering nuclear localization signals in modular protein vehicles for gene therapy. Biochem Biophys Res Commun 2003, 304:625-631. 10.1016/S0006-291X(03)00644-2, 12727199.
60. Peluffo H, Acarin L, Aris A, Gonzalez P, Villaverde A, Castellano B, et al. Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector. BMC Neurosci 2006, 7:35. 10.1186/1471-2202-7-35, 1462999, 16638118.
61. Peluffo H, Aris A, Acarin L, Gonzalez B, Villaverde A, Castellano B. Nonviral gene delivery to the central nervous system based on a novel integrin-targeting multifunctional protein. Hum Gene Ther 2003, 14:1215-1223. 10.1089/104303403767740759, 12952593.
62. Vazquez E, Roldán M, Diez-Gil C, Unzueta U, Domingo-Espin J, Cedano J, et al. Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine 2010, 5:259-268. 10.2217/nnm.09.98, 20148637.
63. Toledo-Rubio V, Vazquez E, Platas G, Domingo-Espin J, Unzueta U, Steinkamp E, et al. Protein aggregation and soluble aggregate formation screened by a fast microdialysis assay. J Biomol Screen 2010, 15:453-457. 10.1177/1087057110363911, 20233904.
64. Vazquez E, Cubarsi R, Unzueta U, Roldan M, Domingo-Espin J, Ferrer-Miralles N, et al. Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials 2010, 31:9333-9339. 10.1016/j.biomaterials.2010.08.065, 20869766.